Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas
- PMID: 24019980
- PMCID: PMC3760851
- DOI: 10.1371/journal.pone.0074738
Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas
Abstract
Recently, the roles of SIRT1 and deleted in breast cancer 1 (DBC1) in human cancer have been extensively studied and it has been demonstrated that they are involved in many human carcinomas. However, their clinical significance for soft-tissue sarcomas has not been examined. In this study, we evaluated the expression and prognostic significance of the expression of SIRT1, DBC1, P53, β-catenin, cyclin D1, and KI67 in 104 cases of soft-tissue sarcomas.
Results: Immunohistochemical expression of SIRT1, DBC1, P53, β-catenin, and cyclin D1 were seen in 71%, 74%, 53%, 48%, and 73% of sarcomas, respectively. The expression of SIRT1, DBC1, P53, β-catenin, and cyclin D1 were significantly correlated with advanced clinicopathological parameters such as higher clinical stage, higher histological grade, increased mitotic counts, and distant metastasis. The expression of SIRT1, DBC1, P53, β-catenin, cyclin D1, and KI67 were significantly correlated with each other and positive expression of all of these predicted shorter overall survival and event-free survival by univariate analysis. Multivariate analysis revealed the expression of SIRT1 as an independent prognostic indicator for overall survival and event-free survival of sarcoma patients. In conclusion, this study demonstrates that SIRT1- and DBC1-related pathways may be involved in the progression of soft-tissue sarcomas and can be used as clinically significant prognostic indicators for sarcoma patients. Moreover, the SIRT1- and DBC1-related pathways could be new therapeutic targets for the treatment of sarcomas.
Conflict of interest statement
Figures
Similar articles
-
Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma.Clin Cancer Res. 2009 Jul 1;15(13):4453-9. doi: 10.1158/1078-0432.CCR-08-3329. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509139
-
Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma.Hum Pathol. 2011 Feb;42(2):204-13. doi: 10.1016/j.humpath.2010.05.023. Epub 2010 Nov 5. Hum Pathol. 2011. PMID: 21056897
-
Acetylation status of P53 and the expression of DBC1, SIRT1, and androgen receptor are associated with survival in clear cell renal cell carcinoma patients.Pathology. 2013 Oct;45(6):574-80. doi: 10.1097/PAT.0b013e3283652c7a. Pathology. 2013. PMID: 24018803
-
Advances on the role of the deleted in breast cancer (DBC1) in cancer and autoimmune diseases.J Leukoc Biol. 2021 Feb;109(2):449-454. doi: 10.1002/JLB.6MR0320-086R. Epub 2020 Apr 26. J Leukoc Biol. 2021. PMID: 32337788 Review.
-
p30 DBC is a potential regulator of tumorigenesis.Cell Cycle. 2009 Sep 15;8(18):2932-5. doi: 10.4161/cc.8.18.9473. Epub 2009 Sep 8. Cell Cycle. 2009. PMID: 19657230 Free PMC article. Review.
Cited by
-
The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.J Ovarian Res. 2015 Feb 15;8:2. doi: 10.1186/s13048-015-0129-3. J Ovarian Res. 2015. PMID: 25823848 Free PMC article.
-
Sirtuins (SIRTs) As a Novel Target in Gastric Cancer.Int J Mol Sci. 2022 Dec 1;23(23):15119. doi: 10.3390/ijms232315119. Int J Mol Sci. 2022. PMID: 36499440 Free PMC article. Review.
-
Deleted in breast cancer 1 as a potential prognostic biomarker in human cancers: a pooled analysis of 2,254 patients.Onco Targets Ther. 2019 Feb 22;12:1563-1574. doi: 10.2147/OTT.S189618. eCollection 2019. Onco Targets Ther. 2019. PMID: 30863120 Free PMC article.
-
Mechanistic insights into the dual role of CCAR2/DBC1 in cancer.Exp Mol Med. 2023 Aug;55(8):1691-1701. doi: 10.1038/s12276-023-01058-1. Epub 2023 Aug 1. Exp Mol Med. 2023. PMID: 37524873 Free PMC article. Review.
-
Sirtuin 7: a new marker of aggressiveness in prostate cancer.Oncotarget. 2017 Aug 24;8(44):77309-77316. doi: 10.18632/oncotarget.20468. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100388 Free PMC article.
References
-
- Chen WY, Wang DH, Yen RC, Luo J, Gu W, et al. (2005) Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123: 437–448. - PubMed
-
- Imai SI, Armstrong CM, Kaeberlein M, Guarente L (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795–799. - PubMed
-
- Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, et al. (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011–2015. - PubMed
-
- Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, et al. (2009) Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 15: 4453–4459. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
